- New agreement aims to provide greater access to millions more high-quality tuberculosis (TB) tests for people living in the least developed countries where the need is most urgent.
- Enables the Global Fund to provide Cepheid's Xpert® MTB/RIF Ultra diagnostic test cartridges for TB at cost, with no profit to Danaher.
WASHINGTON, Sept. 19, 2023 /PRNewswire/ -- Danaher Corporation (NYSE:DHR) ("Danaher"), a global science and technology innovator, today announced it will provide Cepheid's Xpert® MTB/RIF Ultra diagnostic test cartridges for tuberculosis (TB) at Cepheid's cost of $7.97 each to the Global Fund to Fight AIDS, TB and Malaria ("the Global Fund") and to less-developed countries eligible for Cepheid's Global Access Program1 to support greater access to high-quality TB testing. The Global Fund is the largest provider of financing and programs to combat TB globally, ensuring each year that millions of tests are distributed in countries where the need to improve access is greatest.
By reducing the price of Cepheid's Xpert® MTB/RIF Ultra test cartridge to $7.97, Danaher will be selling at its cost and will earn no profit.
The agreement significantly expands a longtime partnership between Cepheid - a Danaher operating company - and the Global Fund to improve access to testing where it matters most. Both Cepheid and the Global Fund are members of a consortium that also includes the Stop TB Partnership, the Global Drug Facility, and the U.S. Agency for International Development (USAID), which aims to increase access to essential diagnostic testing solutions in support of the global goal to end TB around the world by 2030.